Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat

The DOI matches its Crossref record; 28 of the 29 references it cites were found in a registry or an index.

Venlafaxine ER for the Treatment of Pediatric Subjects With Depression

EMSLIE, GRAHAM J., FINDLING, ROBERT L., YEUNG, PAUL P., KUNZ, NADIA R., LI, YUNFENG · 2007 · Journal of the American Academy of Child & Adolescent Psychiatry

Abstract

Objective The safety, efficacy, and tolerability of venlafaxine extended release (ER) in subjects ages 7 to 17 years with major depressive disorder were evaluated in two multicenter, randomized, double-blind, placebo-controlled trials conducted between October 1997 and August 2001.Method Participants received venlafaxine ER (flexible dose, based on body weight; intent to treat, n = 169) or placebo (intent to treat, n = 165) for up to 8 weeks. The primary efficacy variable was the change from baseline in the Children's Depression Rating Scale-Revised score at week 8.Results There were no statistically significant differences between venlafaxine ER and placebo on the Children's Depression Rating Scale-Revised in either study. A post hoc age subgroup analysis of the pooled data showed greater improvement on the Children's Depression Rating Scale-Revised with venlafaxine ER than with placebo (-24.4 versus -19.9; p = .022) among adolescents (ages 12-17), but not among children (ages 7-11). The most common adverse events were anorexia and abdominal pain. Hostility and suicide-related events were more common in venlafaxine ER-treated participants than in placebo-treated participants. There were no completed suicides.Conclusions Venlafaxine ER may be effective in depressed adolescents. However, its safety and efficacy in pediatric patients has not been established. Prescribers should monitor for signs of suicidal ideation and hostility in pediatric patients taking venlafaxine ER.

Overview

Integrity signals

Registry

Crossref · 10.1097/chi.0b013e31802f5f03

Cites

28 of 28 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Citations

Cites

Show all 29 references

Research works printed but not linked: 3

  1. DeVane, 1996, Serotonin selective reuptake inhibitors in child and adolescent psychopharmacology: a review of published experience, J Clin Psychiatry, 57, 55
  2. Kessler, 1998, Epidemiology of DSM-III-R major depression and minor depression among adolescents and young adults in the National Comorbidity Survey, Depress Anxiety, 7, 3, 10.1002/(SICI)1520-6394(1998)7:1<3::AID-DA2>3.0.CO;2-F · DOI · Paper page
  3. Sood, 2004, SSRIs in children and adolescents: where do we stand?, Curr Psychiatry, 3, 83

Cited by

See all 135

Metadata

Authors
EMSLIE, G. J., FINDLING, R. L., YEUNG, P. P., KUNZ, N. R., & LI, Y.
Affiliations
Yale University (US)
Corresponding author
EMSLIE, GRAHAM J.
Venue
Journal of the American Academy of Child & Adolescent Psychiatry
Publisher
Elsevier BV
Published
2007-04
Volume
46
Issue
4
Pages
479-488
ISSN
0890-8567 (ISSN-L)
OpenAlex
W1520036360
Cited by
135
References
29
Citations by year
2026: 2 · 2025: 3 · 2024: 10 · 2023: 5 · 2022: 7 · 2021: 6 · 2020: 4 · 2019: 3 · 2018: 5 · 2017: 9 · 2016: 9 · 2015: 5 · 2014: 8 · 2013: 8 · 2012: 11
FWCI
6.01
Type
journal article
Language
en
Open access
closed
Licence
www.elsevier.com/tdm/userlicense/1.0/ (tdm)
Locations
  • Journal of the American Academy of Child & Adolescent Psychiatry (publishedVersion)
  • PubMed (publishedVersion)
Topics
  • Health Sciences › Medicine › Pharmacology (medical) › Treatment of Major Depression
  • Social Sciences › Psychology › Clinical Psychology › Child and Adolescent Psychosocial and Emotional Development
  • Health Sciences › Medicine › Psychiatry and Mental health › Mental Health Treatment and Access
Keywords
venlafaxine extended release, childhood depression, major depressive disorder, adolescents, Children's Depression Rating Scale-Revised, antidepressant efficacy, adverse events, anorexia, hostility, suicidal ideation, suicide risk, drug safety
MeSH terms
Venlafaxine Hydrochloride, Adolescent, Algorithms, Child, Cyclohexanols, Delayed-Action Preparations, Major Depressive Disorder, Depressive Disorder, Major, Double-Blind Method, Female, Humans, Male, Placebos, Suicide, Attempted, Treatment Outcome, Selective Serotonin Reuptake Inhibitors, Endpoint Determination

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Venlafaxine ER for the Treatment of Pediatric Subjects With Depression. https://app.cochat.ai/papers/10.1097/chi.0b013e31802f5f03
The paper
EMSLIE, G. J., FINDLING, R. L., YEUNG, P. P., KUNZ, N. R., & LI, Y. (2007). Venlafaxine ER for the Treatment of Pediatric Subjects With Depression. Journal of the American Academy of Child & Adolescent Psychiatry. https://doi.org/10.1097/chi.0b013e31802f5f03

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.